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Abstract 
Poor aqueous solubility is currently a prevalent issue in the development of small molecule pharmaceuticals. 
Several methods are possible for improving the solubility, dissolution rate and bioavailability of 
Biopharmaceutics Classification System (BCS) class II and class IV drugs. Two solid state approaches, which 
rely on reductions in order, and can theoretically be applied to all molecules without any specific chemical 
prerequisites (compared with e.g. ionizable or co-former groups, or sufficient lipophilicity), are the use of the 
amorphous form and nanocrystals. Research involving these two approaches is relatively extensive and 
commercial products are now available based on these technologies. Nevertheless, their formulation 
remains more challenging than with conventional dosage forms. This article describes these two technologies 
from both theoretical and practical perspectives by briefly discussing the physicochemical backgrounds 
behind these approaches, as well as the resulting practical implications, both positive and negative. Case 
studies demonstrating the benefits and challenges of these two techniques are presented.  
 
 






Active pharmaceutical ingredients (APIs) are most commonly formulated as crystalline (morphous) solids in  
dosage forms, where the API molecules exhibit long-range order in all directions (with various symmetry 
operators) and form single or polycrystals on the micron scale. Frequently, the same molecules can be 
organized in different arrangements, and this ability of a solid material to exist in more than one crystal form, 
is termed polymorphism. Among drug materials, polymorphism is very common and numerous polymorphs 
may exist for a single molecular species. For example, indomethacin has at least seven different polymorphic 
forms (Surwase et al., 2013).  
In crystals, the regular atomic and molecular pattern, is thermodynamically stabilized through molecular 
conformations and intermolecular interactions that minimize Gibbs free energy. The relative stabilities of 
different molecular arrangements (polymorphs) and conformations, are dictated by the potential energy 
landscape at a given temperature and pressure. While all crystalline polymorphs occupy local minima on the 
potential energy surface, the polymorph with the lowest free energy is that occupying the global minimum 
on the potential energy surface. Theoretically, in crystals all the atoms are perfectly positioned in the 
repeating pattern. However, in reality, the crystals exhibit a variety of crystal defects, such as dislocations 
and point defects, which interrupt the crystal structure. These crystal defects are sites of both higher energy 
and lower mechanical strength. As a result, particle breakage, for example in nanomilling, is more likely to 
take place in these areas. Furthermore, polymorphic transformations, are likely to proceed from these points, 
should the sample be subjected to conditions favoring transformation to another crystal form.    
On the other hand, amorphous (non-crystalline) solids lack long-range order with respect to their atomic 
level structure. The molecules in amorphous APIs are often described as being randomly arranged. In real 
material science, materials are very rarely pure crystalline or pure amorphous (completely random) in 
structure. An example of a 100% pure crystalline material without any crystal defects is single-crystal silicon, 
which is widely utilized in silicon-based discrete components and integrated circuits in electronic equipment 
and solar cells. However, in pharmaceutics, pharmaceutical solids are always positioned somewhere on the 
continuum of order (between randomly arranged molecules and perfectly single crystals). In most 
amorphous solids there is usually some short-range order (e.g. dimer formation due to directional 
intermolecular hydrogen bonding), and in crystalline solids there is always some discontinuity in the structure 
(Figure 1). Complicating the matter still further, the degree of order may not be uniform across the particle 
or sample. For example, the surfaces of the particles frequently exhibit a different degree of crystallinity to 
the core of the particle. This poses challenges not only in the classification of materials as crystalline or 
amorphous, but also in their analysis with different analytical techniques, which are inherently sensitive to 
different length-range orders and sampling volumes. Thus, the analytical limits of the techniques are 
increasingly qualified, by, for example, referring to a material as X-ray amorphous, rather than simply 
amorphous.  
Perfectly amorphous and crystalline solids are two extreme cases of solids, but, as mentioned above, real 
materials are situated somewhere between these two extremes (Figure 1). Nanocrystals can be considered 
intermediate formulations, whose physical properties are also intermediate, and depend on the crystal size. 
The definition of ‘short-range’ vs long-range’ which divides amorphous from crystalline solids is subject to 
interpretation. Crystalline materials have, for example, been depicted as including order (symmetry 
operators) over at least 1000 individual molecules (Bellantone, 2014). If one considers an ‘average’ small 
drug molecule such as indomethacin (with a Mw of 357. 8 g·mol−1), the asymmetric unit of the gamma crystal 
form contains a single molecule, and the unit cell contains two molecules and has axis lengths of 
approximately 1 nm. One thousand ordered molecules in a single direction would result in a single crystal 
size of approximately 500 nm. However, pharmaceutical nanocrystals, are commonly defined as having 
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crystals sizes of down to 100 nm or less, typical sizes in commercialized products being 200-500 nm, and 
indeed indomethacin nanocrystals with sizes of 300-400 nm has been prepared and characterized as 
crystalline, using, for example x-ray powder diffraction and differential scanning calorimetry (Liu et al., 2011; 
Liu et al., 2015). Thus, pharmaceutical solids characterized as amorphous contain much  shorter lengths of 
order, and indeed short range order is commonly described as the predominance of molecular dimers or 
trimers, involving, for example, directional hydrogen bonding between specific molecular  (Strachan et al., 
2007). The molecules in such amorphous solids will inevitably occupy a distribution of molecular 
conformations and intermolecular interactions about the average short-range structure.  
 
Figure 1. Simplified schematic representing degrees of order in pharmaceutical small molecular solids (not 
to scale) and their classifications, as well as the concept of different sensitivities of commonly employed 
analytical techniques. Modified from Bellantone (2014).  
 
Though the chemical composition of different crystalline and amorphous forms of a compound are the same, 
numerous physical properties, such as solubility, physical stability, density, and thermal and optical 
properties, differ. Crystals are thermodynamically stabilized by their long-range order, but the disordered 
amorphous form is a high-energy form and the bonding forces between the molecules are weaker. Of critical 
importance in pharmaceutics, this induces both higher solubility as well as dissolution rate. In nanosized 
crystals, more commonly in pharmaceutics referred to as nanocrystals, the solubility is also increased, while 
the higher surface-to-volume ratio also increases the dissolution rate (Parks et al., 2017). Both the 
amorphous form and nanocrystals lead to a supersaturated solution, i.e. the apparent solubility is higher than 
the thermodynamic solubility of the system. The main drawback of both the amorphous form and 
nanocrystals are their physical instabilities, which is the biggest challenge in their formulation. In amorphous 
solids, the challenge is to avoid crystallization, while with nanocrystals, uncontrolled aggregation and an 
increase in particle size needs to be avoided.  
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When considering the best formulation approach for a poorly soluble API, many alternative solubility 
enhancing formulation approaches to the amorphous form and nanocrystals exist, including salts, co-crystals, 
cyclodextrins, surfactants, co-solvents, and different kinds of lipid systems. In these cases, the higher 
apparent solubility is reached via solubilization. However, these systems have their own limitations. Firstly, 
they feature specific API molecular property prerequisites (e.g. ionizable or co-former groups, or sufficient 
lipophilicity). Secondly, if the higher solubility is reached via solubilization, it does not necessarily lead to 
higher permeation if the drug affinity to the solubilizer is such that it inhibits drug release from the solubilizer 
system into the physiological environment and subsequent permeation (Dahan et al., 2016). The practical 
implications of the latter challenge are illustrated with the example of etoposide. When this API was 
formulated as four different solubility enhancing formulations (cyclodextrin-, surfactant-, and solvent-based 
formulations, as well as amorphous solid dispersion (ASD)), and the formulation effect on apparent solubility 
and permeability was investigated, all four formulations increased the apparent solubility. However, only the 
ASD formulation exhibited a higher apparent permeability (Beig et al., 2015). Accordingly, any enhanced in 
vivo absorption depends upon whether the higher aqueous solubility is reached via solubilization or 
supersaturation (Kuentz 2019). In addition, when permeation is via active transportation, for example with 
Pgp, the higher solubility can saturate the efflux transport system and hence increase the permeability 
(Dahan et al., 2016).While the amorphous form and nanocrystals are often simultaneously considered as 
potential formulation approaches during the industrial development of a poorly water-soluble API, the 
number of articles comparing these two techniques for solubility enhancement is very low.  Two excellent 
review articles have been published in which the scientific backgrounds of nanocrystals and amorphous solid 
dispersions are presented, with the main focus being on formulation and processing, as well as marketed 
products and patent applications involving these methods (Brough and Williams, 2013; Jermain et al., 2018), 
and also reviews handling either nanocrystals (Müller et al. 2011, Li et al. 2016, Bhakay et al. 2018, Peltonen 
and Hirvonen 2018) or amorphous formulations (Grohganz et al., 2013, Laitinen et al., 2014, Edueng et al., 2017) 
are to be found.  
In this context one naturally poses the question, as to whether sufficiently stable amorphous nanosized-
particles can be prepared and utilised, to simultaneously harness benefits of both disorder and nano-sized 
particles. Nanoplexes, in which the nanosized amorphous particles are prepared and stabilised by complexing 
an ionised drug with a polyelectrolyte indeed show dissolution benefits for certain drugs (Cheow and 
Hadinoto, 2012, Lim et al., 2017). However, they rely on the drug being ionisable (like salts).  
This review focuses more generally on the physicochemical and pharmaceutical manifestations of degree of 
order of pharmaceutical solids, without any requirement for ionisation, starting from crystalline material, via 
nanocrystals to the amorphous form. The corresponding characterization methods and associated benefits 
and challenges are reviewed, different formulation considerations are briefly considered, and finally, the 
importance of the characteristic physical properties of these different systems for efficient drug delivery is 
discussed with case studies.  
2. Crystalline solids 
As described above, crystalline materials exhibit long-range positional and orientational order, and different 
molecular arrangements result in polymorphs, which are almost ubiquitous for drug materials (Censi and Di 
Martino, 2015). Polymorphism strongly influences many physical properties, most importantly dissolution 





Figure 2. Plasma concentration levels of thalidomide from two different polymorphs as a function of time  
after oral administration Reprinted from the European Journal of Pharmaceutical Sciences, 136, de Oliveira, 
G.H.O., do Nascimento, S.B., de Oliveira, F.M., Belo, V.S., de Alencar Danda, L.J., Soares-Sobrinho, J.L., Fialho, 
S.L., Bedor, D.C.G., de Castro, W.V., 2019. Systematic evaluation of the impact of solid-state polymorphism 
on the bioavailability of thalidomide, 104937, Copyright (2019) with permission from Elsevier. 
 
Utilization of high throughput crystallization has increased the number of known drug polymorphs, but the 
searches are not exhaustive, and, based on current technologies, it is difficult to exclude the possibility of 
later discovering further polymorphs. Surwase et al. (2013) studied the effect of pH and temperature on 
indomethacin crystallization behavior in aqueous suspensions containing amorphous indomethacin particles, 
and serendipitously discovered that, in addition to the pH and temperature influencing the crystallization 
rate, new polymorphs also appeared. When the samples were held at 5 °C, depending on the pH, three new 
polymorphic forms, ε, ζ, and η, were sequentially observed (Figure 3). Their existence was confirmed by DSC, 




Figure 3. Crystallization path and solution concentration levels of amorphous indomethacin suspensions in 
pH 1.2 at different temperatures. (a) IR spectra PCA scores plot of samples at different time points, (b) IR 
spectra of reference samples and from the suspension at 5 °C at certain time points, (c) solution 
concentration as a function of time. Reprinted with permission from (Surwase, S.A., Boetker, J.P., Saville, D., 
Boyd, B.J., Gordon, K.C., Peltonen, L., Strachan, C.J., 2013. Indomethacin: new polymorphs of an old drug. 
Mol. Pharmaceutics 10, 4472-4480). Copyright (2013) American Chemical Society. 
In some cases, the solubility of different polymorphs are sufficiently similar that no real differences are seen 
in bioavailability values. However, the well-known example of ritonavir, demonstrates that the appearance 
of a previously unknown polymorph can almost totally hinder the drug absorption due to dramatically 
lowered solubility (Chemburkar et al, 2000; Bauer et al., 2001). In 1998 Norvir, a semi-solid capsule 
formulation of ritonavir, failed in control tests with crystals appearing in the formulations. Earlier, from the  
beginning of the discovery phase of the drug’s development until the new drug application (NDA) filing, only 
one crystal form of ritonavir (form I) was known to exist. The crystal structure of ritonavir was thoroughly 
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analyzed using solid state nuclear magnetic resonance (SS-NMR) spectroscopy, near infrared (NIR) 
spectroscopy, X-ray powder diffraction (XRPD) and single crystal X-ray techniques (Bauer et al., 2001) and 
identified as a new form II, which has substantially lower solubility. After discovering form II, its 
heterogeneous nucleation mechanisms were studied. Polymorphic form II exhibits in molecular level a cis 
conformation, which has more stable packing associated with a strong intermolecular hydrogen-bonding 
network. However, precipitation, even when form II seeds are present, is energetically unfavorable unless 
the solution is highly supersaturated. The final outcome of the study was that the high level of 
supersaturation in the solution together with the probable heterogeneous nucleation by a degradation 
product led to the crystallization of form II with significantly lower solubility. Later, in high throughput 
crystallization studies, five crystal forms of ritonavir were observed (Morissette et al., 2003). In addition to 
forms I and II, one metastable polymorph, one hydrated form and one formamide solvate of ritonavir were 
characterized. In fact, hydrates and solvates are not considered polymorphs. Structurally they can be defined 
as co-crystals, where the co-crystal former is either water (hydrate) or some other solvent (solvate).  
If the particle size of any crystalline form of a drug is decreased below the micrometer size range, the material 
properties begin to change. Drug nanocrystals are solid pure drug particles, where the solid drug core is 
generally covered by a stabilizing polymer or surfactant layer (Merisko-Liversidge et al., 2003; Van 
Eerdenbrugh et al., 2008; Shegokar and Müller, 2010; Peltonen and Hirvonen, 2018). Nanosized solid 
particles tend to aggregate very easily, and the polymer or surfactant layer is needed to stabilize the particles 
from aggregation (Wang et al., 2013). The layer also hinders Ostwald ripening. The physical stability of 
nanocrystals mostly relates to the maintenance of particle size, but polymorphic changes (Lai et al., 2011) or 
formation of amorphous material (typically with anti-solvent precipitation or liquid atomization based 
nanocrystallization techniques) (Matteucci et al., 2007) may take place during the production of drug 
nanocrystals, which necessitates careful attention from physical stability point of view. The feasibility of 
nanocrystallization techniques is demonstrated by the fact that the total number of drug applications 
containing nanocrystals for US Food and Drug Administration (FDA) reached over 80 by the beginning of 2017 
(Chen et al., 2017). 
Typical stabilizing polymers for drug nanocrystals include different kinds of cellulose derivatives (Tuomela et 
al., 2014; Ito et al., 2016), polyvinyl pyrrolidone (PVP) (Nakach et al., 2016), poloxamers (Liu et al., 2015), and 
vitamin E TPGS (Ghosh et al., 2012). Surfactants such as polysorbates (Li et al., 2018) or sodium dodecyl 
sulphate (SDS) (Afolabi et al., 2014) have also been used, either alone or in a combination with polymers. 
NMR studies have shown that the nanocrystal particle is formed from a solid drug core, which is surrounded 
by a semisolid phase of drug and stabilizer (Figure 4) (Kojima et al., 2018). The semisolid phase is in 




Figure 4. Schematic presentation of the crystalline solid core, amorphous solid phase and semisolid phase on 
the nanoparticle surface. Semi-solid phase is in equilibrium with the solution phase and it stabilizes the 
nanoparticle by steric hindrance and/or electrostatic repulsion. (CBZ: carbamazepine drug, SAC: saccharose, 
HPMC: hydroxypropyl methyl cellulose, SDS: sodium dodecyl sulphate.) Reprinted with permission from 
(Kojima, T., Karashima, M., Yamamoto, K., Ikeda, Y., 2018. Combination of NMR methods to reveal the 
interfacial structure of a pharmaceutical nanocrystal and nanococrystal in the suspended state. Mol. 
Pharmaceutics 15, 3901-3908). Copyright (2018) American Chemical Society. 
Besides stabilizing the nanosized drug particles, stabilizers also increase solubility via improved wetting. 
Stabilizers are hydrophilic or amphiphilic materials, and when attached to hydrophobic solid drug surfaces, 
the hydrophobic surfaces are become hydrophilic, enhancing wettability and thus solubility, when compared 
to bulk drug (Yang et al., 2019). For example, when the solubility enhancing effect of different stabilizers on 
the solubility of bulk indomethacin was studied, it was found that when the solubility of bulk indomethacin 
in acetate buffer (pH 5.0) was 4.89 µg/ml, the corresponding solubility values in the presence of polysorbate 
80 was 10.90 µg/ml, 6.43 µg/ml with poloxamer F68 and 4.80 µg/ml with poloxamer F127 (Sarnes et al. 2013). 
Both poloxamers as well as polysorbates are widely utilized stabilizers in the production of drug nanocrystals, 
and this study clearly indicates the solubility effect of the stabilizers. Also, amphiphilic surfactants may 
increase the solubility via solubilization. In a study by Sironi et al. (2017), different fenofibrate formulations 
and their dissolution and permeation behavior were studied. It was demonstrated that nanoparticle 
formulation showed supersaturation after dissolution. Further, micellar solubilization increased the apparent 
solubility, although this did not lead to an increased permeation rate. On the other hand, undissolved 
nanoparticles functioned as a drug reservoir, helping to maintain constant drug flow for permeation.     
3. Amorphous solids 
As mentioned in the introduction, amorphous solids lack long-range orientational and positional atomic or 
molecular order (and corresponding symmetry operators), but usually exhibit some degree of short-range 
orientational and/or positional order. Amorphous solids are often defined as a frozen liquid: at the molecular 
level the structure is liquid like, while at the macroscopic level, they have viscosities and hardnesses typical 
for solids. Nevertheless, amorphous and crystalline solids differ in numerous physicochemical properties, 
including mechanical properties and thermal properties, and most importantly, physical (and chemical) 
stability and solubility. Of note, the wettability of amorphous drugs is also better than the corresponding bulk 
crystalline form (Yang et al., 2019). The higher chemical potential of amorphous solids with respect to their 
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(nano)crystalline counterparts, simultaneously results in the higher apparent solubility of amorphous solids, 
as well as the driving force for amorphous materials to crystallize.  
Amorphous forms drugs are seldom sufficiently kinetically stable in pure form in ambient conditions to 
enable their use in pure form. While some such products do exist (Wyttenback and Kuentz, 2017), the API 
molecules in these formulations are typically large and exhibit high degrees of molecular conformational 
flexibility, which serves to inhibit their crystallization.  The bulk of poorly soluble amorphous drugs require 
physical stabilization, and a desire to store medicines at room temperature precludes using low temperatures 
to reduce molecular mobility and hence increase stability. Thus, excipients are added to increase amorphous 
form stability. The three main methods to stabilize the amorphous form are i) polymeric amorphous solid 
dispersions, ii) mesoporous particles, and iii) co-amorphous systems, involving the API and one or more other 
small molecule components (Laitinen et al., 2014). Of these, polymeric solid dispersions have the longest 
history and represent the majority of marketed amorphous drug products. Many excellent reviews about 
amorphous solid dispersions exist (e.g. Laitinen et al., 2014), and thus only a few aspects to consider with 
amorphous solid dispersions are mentioned here.  
Polymeric solid dispersions are generally formulated to be homogeneous single-phase systems (often 
referred to as glass solutions), in which the drug is molecularly dispersed in a highly water soluble amorphous 
(or predominantly amorphous) polymer (e.g. poly(vinyl pyrrolidone, cellulose-based derivatives, or 
amphiphilic polymers). With amorphous solid dispersions produced in combination with water-soluble 
polymer, drug- and carrier-controlled release is demonstrated (Craig 2002). Incidentally, the same 
phenomenon can be seen in loose aggregations of drug nanocrystals, where the stabilizer polymer binding 
particles together rapidly dissolves during the dissolution releasing the individual drug nanoparticles (Craig 
2002; Liu et al., 2011; Liu et al., 2015). 
Often, the solubility of the drug in the polymer is exceeded, and thus kinetic stabilization of the amorphous 
solid dispersion is employed. Stabilization mechanisms include several interrelated phenomena: a) drug-
polymer interactions (e.g. hydrogen bonding), b) reduced molecular mobility of the drugs, and c) steric 
hindrance. Sometimes, some degree of phase separation may be present, with resulting drug- and polymer-
rich amorphous phases (often referred to as glass suspensions). Such phase separation can both reduce 
dissolution and predispose the amorphous dispersion to crystallization during storage and/or administration, 
and thus an understanding of any phase separation and its consequences is required for product 
optimization. Challenges of amorphous polymeric solid dispersions include limited drug loadings, relatively 
high hygroscopicity, and uncontrolled phase separation and ultimately crystallization. Development of new 
methods to characterize and then predict and prevent drug-polymer phase separation, as well as 
crystallization, during production, storage and dissolution, is a very broad and active area of research. In 
particular, predictive approaches to probe drug-polymer solid dispersion formation and stability, are 
gradually helping to bring more efficiency and reliability to stable amorphous solid dispersion development. 
Experimental and computational approaches, considering thermodynamic and kinetic aspects to varying 
degrees, include the use of solubility parameters, Flory-Huggins interaction parameter, molecular 
descriptors, and increasingly, computational molecular modelling. Computational approaches include 
molecular mechanics and dynamics simulations, as well as more quantum mechanics based approaches such 
as density functional theory. While all modelling approaches rely on approximations and assumptions to 
varying degrees and each has its limitations which must be considered, increasing computational power is 
likely to permit increasingly accurate simulation of amorphous solid dispersion formation and stability in 
future (Chakravarty et al., 2017, DeBoyace and Wildfong, 2018). 
More recently, co-amorphous forms have become a viable alternative to polymeric amorphous solid 
dispersions (Laitinen et al., 2012; Löbmann et al., 2017). While single-phase polymeric amorphous solid 
dispersions could equally be considered to be co-amorphous systems, co-amorphous forms generally refer 
10 
 
to single-phase amorphous systems, in which both the API and co-former are small molecules, with typical 
co-former molecules including amino acids and citric acid (Laitinen et al., 2012). Thus, co-amorphous forms 
may be considered the amorphous equivalent of co-crystals. It is interesting however, that co-amorphous 
forms that are easily prepared do not, as a rule, crystallize into the equivalent co-crystals, and if crystallization 
occurs, it is to crystals of the individual components. The stabilization and solubility enhancing mechanisms 
can be considered essentially the same as for the polymeric amorphous dispersions. Importantly, the 
dissolution of co-amorphous forms is generally higher than that of pure amorphous forms, and this has been 
considered some detail elsewhere (Laitinen et al., 2017). Potential advantages over polymeric solid 
dispersions include lower hygroscopicity, possible higher drug loadings, as well as simpler, more precisely 
defined chemical composition. While no known co-amorphous forms have yet reached the market, this is 
expected to change in the near future.  
The third main formulation approach involves mesoporous systems, principally mesoporous silica particles. 
These systems involve nanoscale pores that are large enough to load drug within them, but are too small to 
allow crystallization (including nanocrystallization). Mesoporous formulations are also expected to reach the 
market in the near future, and the systems are well reviewed elsewhere (Laitinen et al., 2012, Maleki et al., 
2017, Bremmell and Prestidge, 2019, Jones and Bimbo, 2020).  
4. Characterization of order 
The toolbox of methods for solid-state characterization is large. However, the structural continuum from 
crystalline to amorphous solids, and as well as structural and thermal variation between differently prepared 
and stored amorphous forms, makes solid state characterization of pharmaceuticals far from simple. 
Compounding this challenge is the fact that different analytical techniques probe different lengths of order 
and solid-state phenomena, and thus have different sensitivities. When faced with characterizing the 
crystallinity of a sample, several questions arise. What technique(s) should be used? How should the data be 
interpreted? How does one define when the sample is amorphous or crystalline? These questions will be 
considered below, with the aid of case studies.  
The most commonly used solid-state analysis methods in pharmaceutics are x-ray diffraction (XRPD) (often 
considered the gold standard for crystallinity analysis), some form of vibrational spectroscopy (infrared (IR), 
Raman, near-infrared (NIR) spectroscopy, or, more recently, terahertz), thermal analysis (differential 
scanning calorimetry (DSC), thermogravimetric analysis (TGA), and isothermal microcalorimetry (IMC)), and 
microscopy (polarizing light microscopy (PLM), scanning electron microscopy (SEM), and, in the case of 
nanocrystals, transmission electron microscopy (TEM)). Many book chapters (in e.g. (Müllertz et al., 2016)) 
and articles review one or a subset of the available solid-state analysis techniques in a pharmaceutical context 
(e.g. spectroscopy (Strachan et al., 2020), and several overviews of all the most commonly used techniques 
are also available (Chieng et al., 2011; Pindelska et al., 2017; Ma and Williams, 2019). An overview of the 
more widely available solid-state analysis techniques is presented in Table 1, together with some theoretical 
features and practical issues.  
 
Table 1. Brief overview of some of the most common techniques for solid-state characterization (modified from 
Novakovic (2020)). 
Technique Benefits Drawbacks Depth resolution (depends 
on setup) 




XR(P)D Crystal form identification, differentiation between 
amorphous and crystalline/nanocrystalline 
quantification of crystallinity, non-destructive 
Preferred orientation effect, lack 
of sampling flexibility in e.g. 
processing environment 





DSC Sensitive including to low levels of crystallinity (seeds 
in amorphous solids), quantification of crystallinity, 
small sample amount (~ µg), information about 
molecular mobility and stability of amorphous solids, 
thermodynamic and kinetic information 
Destructive, inflexible sampling, 
difficult interpretation, slow 
None 
Microscopy and electron microscopy techniques 
 
SEM and AFM Extremely high spatial resolution 
(~ 1 nm), small penetration depth, detailed particle 
morphology/surface information 
Not directly solid-state specific, 
coating and vacuum usually 
required 
Approx. 1 nm or less 
PLM Easy, inexpensive, sensitive to low levels of 
crystallinity 
Limited solid-state specificity, not 
suited to opaque solid dosage 
forms 
Limited in transmission 
Molecular level properties 
 




Signal intensity theoretically proportional to 
concentration, no sample preparation, can be used in 
aqueous systems and processing environments 
Potentially weak signal, slow 
imaging, can be hindered by 
fluorescence, not always 
sufficiently surface specific 
Approx. 5-10 μm 
(microscope) 
ATR-IR Absorbance theoretically proportional to 
concentration, relatively surface specific (can also be 
disadvantage), no sample preparation 
Clamp pressure can induce 
crystallization, water 
interference, inflexible sampling 
Approx. 1-2 μm 
ssNMR Rich qualitative and quantitative solid-state 
information, sensitive to low levels of crystallinity, 
information on asymmetric unit in crystals 
Slow analysis (hours) None 
 
Different analytical methods have been shown to provide different results when determining the crystallinity 
of the same samples. One example of such an analytical challenge concerns the preparation of amorphous 
material by milling (Mah et al., 2014). Mah et al (2014) used dry milling to convert crystalline glibenclamide 
into the amorphous form. The solid-state form of the material was characterized after different milling times 
by X-ray powder diffraction (disappearance of diffraction peaks), Raman spectroscopy (spectral changes 
detected by principal component analysis of the Raman spectra), and differential scanning calorimetry 
(change in crystallization onset temperature). According to XRPD, the sample was amorphous after 30 min 
of milling, while the sample reached maximum disorder after 60 min and 180 min according to the Raman 
spectroscopic and DSC analyzes, respectively. These differences in sensitivity can be attributed to the 
different phenomena being probed by these techniques. X-ray powder diffraction detects the presence of a 
lattice structure and once the length scale of unit cell alignment is insufficient (perhaps less than 
approximately 5-10 unit cells) for lattice diffraction and constructive x-ray interference, the sample will 
appear amorphous with x-ray diffractogram characterized by an amorphous ’halo’, even though shorter-
range order remains. Raman (and infrared) spectroscopy, on the other hand, probes intra- (and 
inter)molecular vibrations, and thus is theoretically more sensitive to shorter range order than XRPD. Several 
features, or thermal events, in DSC thermograms can be used as indicators of crystallinity (e.g. presence of a 
glass transition temperature (Tg), change in heat capacity at the Tg, enthalpy of crystallization, as well as 
onset of crystallization). In this study, the onset of crystallization showed systematic change for a longer 
period (up to 180 min of milling) than the other phenomena. This may be attributed to the presence and 
then loss of residual crystallites or nuclei during milling, which still catalyze crystallization during the DSC 
measurement, even after this level of order is too low to be detected with the x-ray or vibrational 
spectroscopy methods employed.  
When considering the practical value of the different analytical methods, the link to critical quality attributes 
is crucial. In this case, the storage stability and dissolution behavior of glibenclamide was probed after 
different milling times. The onset of crystallization with DSC analysis was the phenomenon that was best 
correlated with both storage stability and dissolution behavior.  
Another factor to consider is sampling volume and crystallinity distribution within the sample. For example, 
some analytical methods (also depending on the sampling setup) are highly surface biased (e.g. FTIR with an 
attenuated total reflective (ATR) sampling accessory), while others have no surface bias (e.g. DSC) (Table 1). 
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Crystallization is frequently surface biased (Yu, 2016; Mah et al., 2017; Novakovic et al., 2018), especially 
below Tg, and in this situation, the more surface biased techniques tend to suggest faster crystallization than 
reality (if the whole sample is considered). However, surface crystallinity can be more important than overall 
crystallinity when considering the critical quality attribute of dissolution, since dissolution occurs at particle 
surfaces (Novakovic et al., 2020; Priemel et al., 2012).  
5. Solubility enhancement  
When the crystalline material is converted into nanocrystals or the amorphous form, the concentration 
during dissolution increases above the thermodynamic equilibrium solubility level and a supersaturated 
solution is formed (Colombo et al., 2017). This supersaturated solution has excess Gibbs free energy, and 
thus there is a tendency for the solute to separate from the solution by nucleation and crystal growth, i.e. 
forming a solid phase. Nucleation and crystal growth are affected by the level of supersaturation, and start 
after the critical supersaturation concentration value is reached. The level of solubility increase is related to 
the level of chemical potential of the amorphous or nanocrystalline form and by how much it exceeds the 
corresponding value for the crystal form. The nucleation and crystal growth kinetics and mechanisms depend 
on concentration: a lower initial concentration favors particle growth instead of nucleation while higher initial 
concentrations favour nucleation (Haruta and Delmon, 1986). In vivo, this is reflected in competing actions 
between permeation/absorption and precipitation. Precipitation can also be affected by the presence of 
polymers or other excipients (e.g. small molecule co-amorphous coformers) into the system (Xu and Dai, 
2013; Sarode et al., 2014). Formation of a drug-polymer (or other excipient) mixture decreases the chemical 
potential of the amorphous drug. These precipitation inhibitors can inhibit or delay the drug precipitation, 
allowing better absorption. 
Fast dissolution followed by supersaturated solution and precipitation are described by spring and parachute 
theory (Figure 5). The spring occurs when a supersaturated and thermodynamically unstable solution of a 
drug is produced from a higher energy solid-state form or an extremely fast dissolving form of the material 
(amorphous form, nanosized particles). If the drug precipitates, the supersaturation (spring) is lost. However, 
by adding precipitation inhibitors, higher concentration levels can be maintained (parachute), and 
maintaining the supersaturation for a sufficient period of time can lead to a higher absorption in vivo and 
increased bioavailability. In Equation 1, the degree of supersaturation, S, describes the driving force for 
precipitation   
S=CB/CS ,   (1) 
where CB is the total solute concentration and CS is the equilibrium concentration of the material. The rule is 




Figure 5.  Theoretical presentation of solution concentration as a function of time for i) crystalline drug (black, 
dashed), ii) pure amorphous drug (black), and solid dispersion with two different polymers: iii) polymer A 
(medium grey) and iiii) polymer B (light grey). From the figure, it can be seen that all three amorphous 
formulations have a ‘spring effect’.  The difference between the two polymers is that the polymer A exerts a 
parachute effect while polymer B completely inhibits recrystallization and maintains the original degree of 
supersaturation. Reproduced from (Laitinen et al., 2014) with permission from Springer. 
Typical precipitation inhibitors are polymers, mostly studied being cellulose derivatives (MC, HPC, HPMC, 
HPMCAS) and vinyl polymers (PVA, PVP, PAA (polyacrylic acid, polyvinylpyrrolidone vinyl acetate (PVPVA), 
but also surfactants, cyclodextrins and potentially co-amorphous form formers (Figure 6).  
 
Figure 6. Effect of PVP on crystal growth of bicalutamide in supersaturated solutions. After addition of 
crystalline nanoparticles to supersaturated solutions, presence of PVP (right curve) delays the crystal growth. 
Reprinted from International Journal of Pharmaceutics, 453, Xu, S., Dai, W.-G., Drug precipitation inhibitors 




Mechanistically, precipitation inhibition can be divided into two different groups: thermodynamic or kinetic 
inhibition (Xu and Dai, 2013). Thermodynamic inhibition is based on higher solubility, which lowers the 
degree of supersaturation. Surfactants and cyclodextrins behave in this way. Kinetic inhibition is reached via 
inhibition or retardation of precipitation, for example via interfering with crystal nucleation and/or crystal 
growth. In general, polymers inhibit precipitation kinetically, due to interactions with the drug material or 
other changes in the solution environment. For example, polymers can adsorb onto the drug particle 
surfaces. Interactions can be hydrogen bonding based, ionic, or hydrophilic/hydrophobic interactions. 
Rigidity/flexibility of the polymer chain, as well as molecular weight and viscosity may have an effect, the 
interplay of which is not yet fully elucidated. 
There is growing evidence that the molecular interactions between the drug and the polymer have the most 
significant impact on the saturation solubility enhancement (Al-Obaidi et al., 2013; Fu et al., 2018; Li and 
Taylor, 2018). Baghel et al. (2016) studied various amorphous solid dispersion systems with drug-polymer 
combinations, and found that those that were capable of forming interspecies hydrogen bonds in the solution 
state were most effective in prevention of drug crystallization. Similarly, with different grades of 
hydroxypropyl methylcellulose, the presence of hydroxypropyl groups that are capable of hydrogen bonding 
and strong drug-polymer interactions was the most important property for maintaining supersaturation 
(Hong et al., 2018). In the same way, the saturation solubility of amorphous griseofulvin was improved with 
the addition of hydroxypropyl methylcellulose acetate succinate (HPMCAS) due to hydrogen bonding, but 
increase in the saturation solubility with polyvinyl pyrrolidone (PVP) was much lower (Al-Obaidi et al., 2013). 
The precipitation of amorphous carbamazepine has been inhibited by interactions between the acetate and 
succinate groups of hypromellose acetate succinate (HPMC-AS) and carbamazepine (Ishizuka et al., 2019). 
Acetate and succinate groups disturbed intermolecular carbamazepine interactions in amorphous 
carbamazepine by forming polymer carbamazepine interactions with C=O and NH2 groups in carbamazepine. 
Precipitation inhibition may also be based on hydrophilic/hydrophobic interactions, as was the case when 
the higher polymer hydrophobicity led to increased amorphous stability of ethenzamide (Frank and Matzger, 
2019).  
It has also been shown that the theoretically calculated free enthalpy of mixing correlated positively with 
maintaining the supersaturated state (Price et al., 2019). However, formulation factors and process 
conditions, including mixing homogeneity of the drug and polymer, affect interaction formation and hence 
also the dissolution behavior of amorphous solid dispersions (Chen et al., 2016). Also the production method 
(spray-drying vs. milling or mixing vs. predissolving) affected the degree of supersaturation with the same 
polymer-drug mixtures, probably via structural effects of the production method (Surwase et al., 2015). 
Changes in pH conditions can also affect supersaturation maintenance (Xie et al., 2017). 
Though with poorly soluble drug materials the rate limiting step for maximum absorption is the dissolution 
rate, it is good to be aware of that if the solubility is increased dramatically via supersaturated formulations, 
the rate limiting step may shift from solubility to absorption rate. Accordingly, stabilization of drug solubility 
(supersaturated state) for a longer time period is very important. 
6. Performance in formulations: a comparison of amorphous drug and nanocrystals   
As already mentioned, in pharmaceutical research the increasing interest in using the amorphous form and 
nanocrystals is based on their ability to improve solubility properties, and both these systems are based on 
higher solubility via supersaturation (Kawakami, 2012; Taylor and Zhang, 2016). Both techniques have been 
used for solubility improvement (Table 2) and some studies have been published in which the two 
approaches have been compared. In a study by Zhang et al. (2013), an amorphous solid dispersion 
formulation of itraconazole outperformed nanocrystal  system (Zhang et al., 2013). However, another study 
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suggested that nanocrystals can outperform amorphous solid dispersions with respect to fast dissolution of 
low-dose drugs (Li et al., 2017). Both these studies are described in more detail below.  
Table 2. Some selected examples of nanocrystalline and amorphous based commercial drug products 
(modified from Bobo et al. 2016, Chen et al. 2017, Wyttenbach and Kuentz 2017, Malamatari et al. 2018, 










Gris-PEG® Griseofulvin - Coprecipitation Oral tablet 
Naprelan® Naproxen sodium - Media milling Oral tablet 
Verelan®PM Verapamil - Media milling Oral capsule 
Emend® Aprepitant - Media milling Oral capsule and 
oral suspension 
,Azopt® Brinzolamide - Media milling Ocular suspension 
Triglide® Fenofibrate - Jet-stream 
homogenization 
Oral tablet 





Ryanodex® Dantrolene sodium - Not available injection (iv) 
Amorphous (pure drug) 
Ceftin® Cefuroxime axetil - - Oral tablet 
Viracept® Nelfinavir mesylate - - Oral tablet 
Accupril® Quinapril hydrochloride 
- - Oral tablet 
Crestor® Rosuvastatin calcium - - Oral tablet 
Accolate® Zafirlukast - - Oral tablet 
Amorphous (solid dispersion) 
Intelence® Etravirine HPMC Spray drying Oral tablet 
Certican®/Zortress® Everolimus HPMC Spray drying Oral tablet 
Fenoglide® Fenofibrate PEG Spray melt Oral tablet 




PVP VA 64 
Spray layering (bead 
coating)/ 
Melt extrusion 
Oral tablet / 
Oral tablet 
Kalydeco® Ivacaftor HPMCAS Spray drying Oral tablet 
Kaletra® Lopinavir and Ritonavir PVP VA 64 Melt extrusion Oral tablet 
Cesamet® Nabilone PVP Melt extrusion Oral capsule 
Afeditab® CR Nifedipine Poloxamer or PVP 
Melt/absorb on 
carrier Oral tablet 
Nivadil® Nilvadipine HPMC n.a.a Oral tablet 
Nimotop® Nimodipine PEG Spray drying/fluid bed Oral tablet 
Noxafil® Posaconazole HPMCAS Melt extrusion Oral tablet 










Incivek®/Incivo® Telaprevir HPMCAS Spray drying Oral tablet 
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Rezulin®b Troglitazone PVP Melt extrusion Oral tablet 
Zelboraf® Vemurafenib HPMCAS Coprecipitation Oral tablet 
Isoptin® SR-E 240 Verapamil hydrochloride HPC/HPMC Melt extrusion 
Oral tablet 
 
Of course, even higher benefits can be obtained, if the amorphous drug is formulated as nanosized particles, 
where the high supersaturation solubility based on the amorphous form and fast dissolution due to the large 
specific surface area of the nanoparticles are combined (Cheow et al., 2014; Bi et al., 2015). While these 
comparisons clearly demonstrate that both the amorphous form and nanosizing can demonstrate 
substantially enhanced dissolution, producing the amorphous form or nanocrystals is only the first step, and 
the role of the final formulation and careful formulation planning is required for successful and optimized in 
vivo performance of these systems. 
Sarnes et al. (2014) produced solid oral itraconazole nanocrystal formulations. Itraconazole nanocrystals 
were produced by wet milling and then either freeze-dried or granulated and, finally, incorporated into tablet 
or capsule formulations. The in vitro drug release for nanocrystalline formulations was immediate and much 
faster than the commercial product (Sporanox® capsules), which is composed of pellets covered by the drug 
in an ASD. But, in vivo, the relative bioavailability of the nanocrystal formulation was only 27.6 to 39.9%  of 
that of Sporanox®. The key for successful in vitro/in vivo correlation with nanosystems requires an 
understanding of solubilization, precipitation inhibition as well as stabilization of supersaturation, in which 
immediate release itraconazole nanocrystal formulations failed in this study. The fast dissolution of the 
itraconazole from the nanocrystals was immediately followed by precipitation due to the fast transit time of 
dissolved itraconazole to the small intestine, where the solubility of itraconazole is approximately 250-fold 
lower than in the stomach. However, when itraconazole nanocrystals were bound to nanofibrillar cellulose 
fibers with cellulose binding domains, the relative bioavailability of nanocrystalline formulations increased 
to between  119 to 128% of the commercial product (Sporanox® granules) (Valo et al., 2011). In this case, the 
formulation containing nanocrystals bound nanofibrillar cellulose matrices retained the nanocrystals for 
longer in the optimal dissolution and absorption region of the gastrointestinal tract.  
In a comparison of amorphous itraconazole formulations, Yin et al. (2015) formulated itraconazole as an 
amorphous form in solid dispersion by supercritical fluid technology. In this study, the relative bioavailability 
of the itraconazole amorphous solid dispersion was 120% when compared to the commercial Sporanox® 
granules. Together, these above described studies reveal that, with itraconazole, formulations containing 
either nanocrystals or the amorphous form were able to reach similar levels of bioavailability . The most 
important take-home message here is that the production of nanocrystals or amorphous form is just a first 
step. The successful final performance of the product in vivo is highly dependent of the final formulation. 
Expanding the nanocrystal/amorphous formulation comparison to other drugs, Li et al. (2017) used 
hydroxypropyl cellulose and Soluplus® in stabilizing wet milled griseofulvin nanosuspensions. After milling, 
the nanosuspensions were extruded and dry-milled. A wet-milled nanosuspension was also spray-dried. Two 
kinds of drug formulations were prepared depending on the drug-polymer solubility properties: extrudates 
with i) nano/micro-crystalline drug particles in a hydroxypropyl cellulose matrix, and ii) an amorphous solid 
dispersion, with the amorphous drug molecularly dispersed within the Soluplus® matrix. In vitro, the 
nanosystems dissolved faster than the amorphous solid dispersions. In another study (Zhang et al., 2013), an 
itraconazole-Soluplus® solid dispersion extrudate exhibited faster dissolution and increased oral absorption 
when compared with an itraconazole nanocrystals. 
Mah et al. (2014) studied amorphous glibenclamide produced by milling, as described above in Section 4. 
The amorphous form was confirmed with XRPD, Raman spectroscopy and DSC to have reached maximum 
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disorder after 180 minutes (Figure 7). When these amorphous samples were subjected to intrinsic dissolution 
testing using a flow through set-up, after 10 minutes of dissolution the dissolved drug concentration was 
approximately 2 µg/ml, and after 20 minutes it was approximately 4 µg/ml. Later, glibenclamide was also 
formulated as drug nanocrystals with poloxamer 188 or HPMC as a stabilizer (unpublished data). The smallest 
particles (mean particle size approximately 265 nm) were reached with poloxamer 188 as the stabilizer. In 
the same intrinsic dissolution test equipment and environment, as in the study by Mah et al. (2014) with 
amorphous glibenclamide, the solution concentration was 2.1 µg/ml after 10 minutes of dissolution testing, 
and 3.4 µg/ml after 20 minutes. Intrinsic dissolution testing involves the measurement of dissolution from a 
flat surface and defined surface area, which eliminates the effect of surface area effect (due to the different 
particle sizes) on dissolution. However, these two studies (Mah et al., 2014; unpublished data) showed 
corresponding intrinsic dissolution value levels for both amorphous and nanocrystalline glibenclamide. 
 
Figure 7. XRPD patterns of glibenclamide samples after different milling times. After 30 minutes milling, 
glibenclamide is x-ray amorphous, but the sample continued to become more disordered until 60 min 
according to Raman spectroscopy (as determined by spectral changes detected with the aid of principal 
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components analysis (PCA)), and 180 min according to DSC (as determined by the increase in crystallization 
onset temperature). Reprinted with permission from (Mah, P.T., Laaksonen, T., Rades, T., Aaltonen, J., 
Peltonen, L., Strachan, C.J., 2014. Unravelling the relationship between degree of disorder and the dissolution 
behavior of milled glibenclamide. Mol. Pharmaceutics 11, 234-242). Copyright (2014) American Chemical 
Society. 
Finally, when the performance of amorphous nanostructured aggregates and wet-milled drug nanocrystals 
was compared for pulmonary drug delivery, in vitro dissolution rates were similar but the amorphous system 
reached a 4.7-fold higher degree of supersaturation than the nanocrystals (Yang et al., 2010). After 
inhalation, the in vivo lung depositions of both the systems were equivalent. However, the AUC0-24 value of 
the amorphous system was approximately 3.8-fold higher than that of the nanocrystalline formulation, due 
to the higher degree of supersaturation and consequent permeation. Of note, the study reported particle 
sizes (d50 values) of 570 nm for the drug nanocrystals and 250 nm for the amorphous nanosystems. 
Accordingly, also the smaller particle size of amorphous systems further served to increase the level of 
supersaturation and subsequent permeation. 
7. Conclusions 
Most new small molecule pharmaceuticals suffer from poor solubility, and formation of the amorphous form 
and nanocrystallization are two increasingly popular methods to overcome this challenge. Over the two last 
decades, research with these two approaches has blossomed and an increasingly large portfolio of 
commercial products based on these techniques is available on the market. An advantage of these 
technologies over other solubility or dissolution enhancing methods, is the lack of preconditions with respect 
to molecular properties. The improvement in solubility with both of these techniques is based on formation 
of the supersaturated state. However, there are differences between these two techniques in terms of 
production, characterization, physical stability and formulation approaches. The main advantages of drug 
nanocrystals are their simplicity and fast production, but the challenge is to avoid aggregation of nanosized 
particles. With the amorphous form, it is possible to reach very high levels of supersaturation, but the 
challenge is in stabilization of the amorphous form from crystallization. With both the systems, the 
maintenance of supersaturation after dissolution requires extra care. The success of both these techniques 
has already been shown with the increasing number of amorphous or nanocrystalline products entering the 
market. The number of new drug applications based on these two approaches is expected to continue to 
increase.  
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